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The mitochondrial NADH dehydrogenase (complex I) in mammalian cells is a multimeric enzyme consisting
of ;40 subunits, 7 of which are encoded in mitochondrial DNA (mtDNA). Very little is known about the
function of these mtDNA-encoded subunits. In this paper, we describe the efficient isolation from a human cell
line of mutants affected in any of these subunits. In the course of analysis of eight mutants of the human cell
line VA2B selected for their resistance to high concentrations of the complex I inhibitor rotenone, seven were
found to be respiration deficient, and among these, six exhibited a specific defect of complex I. Transfer of
mitochondria from these six mutants into human mtDNA-less cells revealed, surprisingly, in all cases a
cotransfer of the complex I defect but not of the rotenone resistance. This result indicated that the rotenone
resistance resulted from a nuclear mutation, while the respiration defect was produced by an mtDNA mutation.
A detailed molecular analysis of the six complex I-deficient mutants revealed that two of them exhibited a
frameshift mutation in the ND4 gene, in homoplasmic or in heteroplasmic form, resulting in the complete or
partial loss, respectively, of the ND4 subunit; two other mutants exhibited a frameshift mutation in the ND5
gene, in near-homoplasmic or heteroplasmic form, resulting in the ND5 subunit being undetectable or strongly
decreased, respectively. It was previously reported (G. Hofhaus and G. Attardi, EMBO J. 12:3043–3048, 1993)
that the mutant completely lacking the ND4 subunit exhibited a total loss of NADH:Q1 oxidoreductase activity
and a lack of assembly of the mtDNA-encoded subunits of complex I. By contrast, in the mutant characterized
in this study in which the ND5 subunit was not detectable and which was nearly totally deficient in complex
I activity, the capacity to assemble the mtDNA-encoded subunits of the enzyme was preserved, although with
a decreased efficiency or a reduced stability of the assembled complex. The two remaining complex I-deficient
mutants exhibited a normal rate of synthesis and assembly of the mtDNA-encoded subunits of the enzyme, and
the mtDNA mutation(s) responsible for their NADH dehydrogenase defect remains to be identified. The
selection scheme used in this work has proven to be very valuable for the isolation of mutants from the VA2B
cell line which are affected in different mtDNA-encoded subunits of complex I and may be applicable to other
cell lines.
NADH:ubiquinone oxidoreductase (complex I) is the largest
and most complicated of the enzymes of the mitochondrial
respiratory chain (15, 31, 35). With a molecular mass of ;900
kDa and the presence of about 40 different subunits, the com-
plexity of mammalian complex I approaches that of the ribo-
some. The reason for this level of complexity is unknown.
Complex I from mammalian cells and Neurospora crassa con-
tains seven subunits that are encoded in mitochondrial DNA
(mtDNA) (2, 3, 35). Despite the fact that the primary struc-
tures of the mammalian mtDNA-encoded subunits were de-
termined 13 years ago (1), still little is known about their
function. The subunit encoded in the mitochondrial ND1 gene
binds rotenone, a specific inhibitor of complex I (6), and in-
teracts with ubiquinone, the natural electron acceptor (10). In
addition, the ND1 gene product may be involved in proton
translocation, because it binds N,N9-dicyclohexylcarbodiimide
(37). An insight into the function of the mtDNA-encoded
subunits of complex I has come from their localization within
complex I. By electron microscopy, the enzyme from N. crassa
has been shown to have an overall L-shaped structure (17), and
it is likely that this model applies also to the mammalian
enzyme. One arm of the L is buried in the inner mitochondrial
membrane, while the other protrudes into the matrix. The
membrane arm has been isolated and shown to contain all the
mtDNA-encoded subunits, while the matrix arm contains most
of the nucleus-encoded subunits and most of the prosthetic
groups that are involved in the redox reactions between
NADH and ubiquinone (35). Complex I uses the energy gen-
erated by these reactions to pump protons out of the mito-
chondrial matrix, thereby generating an electrochemical gra-
dient across the inner mitochondrial membrane. The above
observations, therefore, support involvement of the membrane
arm of the enzyme and of the mtDNA-encoded subunits in
proton translocation. The importance of the mtDNA-encoded
subunits is further emphasized by the fact that the much sim-
pler bacterial counterpart of complex I contains subunits ho-
mologous to all seven mtDNA-encoded polypeptides of the
mammalian enzyme (34, 38).
In the past few years, the mtDNA-encoded subunits of com-
plex I have attracted increasing attention as a result of the
discovery that mutations in the genes for these subunits can
cause a disease in humans. In particular, it has been shown that
mutations in the ND4 gene (33), the ND1 gene (18–20), and
the ND6 gene (21) can be the primary cause of Leber’s hered-
itary optical neuropathy, with mutations in other ND genes
contributing to the severity of the syndrome (32). Further-
more, for some of these mutations, a reduction in the activity
of the enzyme has been reported (24, 25, 28). It is also con-
ceivable that some of these mutations affect proton transloca-* Corresponding author.
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tion. A deeper understanding of the functions of the mtDNA-
encoded subunits of complex I will be necessary to explain at
the molecular level the pathogenetic mechanism(s) of these
mutations and other possible disease-causing mutations affect-
ing these subunits. Progress in this understanding has been
hampered by the complexity of the enzyme and the scarcity of
mutants available.
Recently, in the course of an analysis of rotenone-resistant
variants of the human cell line VA2B, a complex I-deficient
mutant lacking the mitochondrial ND4 gene product because
of a frameshift mutation in the gene has been identified and
characterized (16). In the present study, an extension of the
analysis to seven other rotenone-resistant mutants has, surpris-
ingly, revealed that five of these mutants also exhibited a defect
in any of the mtDNA-encoded subunits of respiratory chain
NADH dehydrogenase. Furthermore, among these defective
mutants, one carried, in heteroplasmic form, the same ND4
frameshift mutation previously identified, while two others
contained a frameshift mutation in the ND5 gene either in
near-homoplasmic or in heteroplasmic form. An analysis of the
mutant almost completely lacking the ND5 subunit showed
that this subunit is essential for complex I activity, but, in
contrast to the ND4 subunit, the absence of the ND5 subunit
does not prevent the assembly of the membrane arm of the
complex. The mutant selection scheme applied in this study to
VA2B cells has thus proved to be a valuable means for the
isolation from this cell line of mutants affected in different
mtDNA-encoded subunits of the enzyme.
MATERIALS AND METHODS
Cell lines and media. The human cell line VA2B (27) was grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% calf serum and 3 mg
of 8-azaguanine per ml. The 143B.TK2 cell line was grown in DMEM supple-
mented with 5% fetal bovine serum and 100 mg of bromodeoxyuridine (BrdU)
per ml. The r0206 cell line (23), a derivative of 143B.TK2 cells, was grown in
DMEM supplemented with 5% fetal bovine serum, 50 mg of uridine per ml, and
100 mg of BrdU per ml.
Isolation of rotenone-resistant VA2B cell mutants. Ten plates of VA2B cells
(;4 3 105 cells per plate) in DMEM with 10% calf serum and 3 mg of 8-aza-
guanine per ml were exposed to 0.4 mM rotenone and maintained continuously
in the presence of this concentration of the drug, with frequent medium changes
(every 3 or 4 days). After 3 weeks, ;1,400 clones were obtained from the 10
plates. Ten independent rotenone-resistant clones (picked one from each plate)
were subjected to increasing concentrations of the drug, and eight clones were
adapted to grow in medium containing 1 mM drug (after 1 to 3 months from their
isolation, with the exception of C7, which was maintained for 7 months in 0.4 mM
rotenone and thereafter proved to be resistant to 1 mM rotenone). They were
then maintained for 8 to 17 months (4 weeks for C7) at this concentration of the
drug. To test the VA2B cells and the VA2B-derived clones for their rotenone
resistance, cell cultures (33 105 cells per 10-cm-diameter dish) were exposed for
5 days to the indicated concentrations of the drug, and then cells were counted.
Transfer of mitochondria from rotenone-resistant mutants into r0206 cells. r0
cell transformation by cytoplast fusion was carried out as previously described
(23), using clones that had been maintained in 1 mM rotenone for 8 to 17 months
(4 weeks for C7). Transformants were isolated in DMEM supplemented with 5%
dialyzed fetal bovine serum and 100 mg of BrdU per ml. Four to six weeks after
their isolation, the BrdU was omitted from the medium. Rotenone resistance of
the 143B.TK2 cells and of the r0 transformants was tested as described in the
previous paragraph, except that the cells were plated at 2 3 105 per dish.
O2 consumption measurements. VA2B-derived mutant cell lines were grown
in rotenone-free medium for 24 h prior to the measurements. O2 consumption
determinations for intact cells were carried out as previously described (23). For
measurements of O2 consumption by digitonin-permeabilized cells (13), about
107 cells were harvested by trypsinization and resuspended in 1 ml of buffer (10
mM HEPES [N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid; pH 7.1], 10
mM MgCl2, 250 mM sucrose), and then 100 to 150 mg of digitonin (1 to 1.5 ml
of a 10% dimethyl sulfoxide solution) was added while the suspension was being
mixed; after addition of 9 ml of buffer, the cells were pelleted and resuspended
in ;100 ml of buffer. After introduction of the cells into the chamber of a Gilson
5/6 Oxygraph containing 1.7 ml of respiration medium (20 mM HEPES [pH 7.1],
250 mM sucrose, 2 mM KPi, 10 mM MgCl2, and 1.0 mM ADP), two small
aliquots were removed to determine the exact number of cells in the chamber.
Substrates and inhibitors from 1003 stock solutions (neutralized with NaOH
when necessary) were added with Hamilton syringes. The final concentrations
were as follows: malic acid, 5 mM; glutamic acid, 5 mM; succinic acid, 5 mM; Na2
glycerol-3-phosphate, 5 mM; ascorbic acid, 11 mM; N,N,N9,N9-tetramethyl-p-
phenylenediamine (TMPD), 0.2 mM; rotenone, 100 nM; antimycin, 4 nM; and
KCN, 1 mM.
NADH:Q1 and NADH:K3Fe(CN)6 oxidoreductase activity measurements. The
mitochondrial fraction was isolated from ;0.5 ml of packed cells as described
elsewhere (30), resuspended in 8 ml of 10 mM Tris (pH 7.5) at 48C, and sonicated
for 40 s (four 10-s pulses separated by 15-s intervals) in a polycarbonate tube
immersed in ice water. Mitochondrial membranes were pelleted by centrifuga-
tion at 39,000 rpm in a Beckman Ty 65 fixed-angle rotor for 60 min and resus-
pended in the buffer described above at a protein concentration (determined by
the Bio-Rad assay) of about 5 mg/ml. The oxidoreductase activities were mea-
sured, at protein concentrations of 85 to 120 mg/ml for Q1 reduction and 20 to 35
mg/ml for K3Fe(CN)6 reduction, in a mixture containing 20 mM Tris (pH 7.5), 1
mM KCN, 100 mMNADH, and 50 mMQ1 (Eisai Co., Japan) or 1 mM Fe(CN)6.
The reaction was monitored at 275 nm for the reduction of Q1 (ε 5 12,250 M21
cm21) and at 410 nm for the reduction of K3Fe(CN)6 (ε 5 1000 M21 cm21). The
NADH:Q1 oxidoreductase activity of the VA2B control was .95% sensitive to
100 nM rotenone.
Mitochondrial protein synthesis analysis. Labeling was performed as de-
scribed by Chomyn et al. (4). Samples of 106 VA2B or r0 transformant cells were
plated on 5-cm-diameter dishes and grown overnight. After the cells were
washed with methionine-free DMEM, 5 ml of the same medium containing 100
mg of emetine per ml was added to each plate. After 10 min of incubation,
[35S]methionine (0.1 mCi) was added and the plates were incubated for 2 h at
378C. The cells were then trypsinized, washed, and lysed in 1% sodium dodecyl
sulfate (SDS). Samples containing 26 to 150 mg of protein were electrophoresed
through an SDS–15 to 20% exponential gradient polyacrylamide gel.
Immunoprecipitation experiments.As described by Chomyn et al. (3), samples
of 2 3 106 cells were plated on 10-cm-diameter dishes, grown for 22 h in the
presence of 40 mg of chloramphenicol per ml to accumulate nucleus-encoded
subunits of complex I, washed with methionine-free DMEM to remove chlor-
amphenicol and methionine, incubated for 10 min in the same medium with 100
mg of cycloheximide per ml, and then exposed for 2 h to 1 mCi of [35S]methi-
onine. Thereafter, the cells were washed and subjected to a 15-h chase in
complete unlabeled medium to allow the incorporation of the labeled mtDNA-
encoded subunits into complex I. The cells were then trypsinized, washed, and
mixed with 0.1 ml of packed HeLa cells, and the mitochondrial fraction was
isolated by homogenization and differential centrifugation and lysed in 0.5%
Triton X-100. Samples containing 120 mg of protein were incubated at 48C with
72 mg of gamma globulins from an antiserum against the 49-kDa subunit of
bovine complex I (2), from an antiserum against the C-terminal undecapeptide
of subunit II of human cytochrome c oxidase (COII) (26), or from normal rabbit
serum. The mitochondrial proteins of transformant C6T exhibited, after pulse-
chasing, about one-third the specific activity observed in VA2B cells and in the
other transformants (see below). Therefore, an approximately threefold-larger
amount of protein (380 mg) was used in the immunoprecipitation experiments.
Immunocomplexes were bound to formaldehyde-fixed Staphylococcus aureus
(Zysorbin; Zymed) (2), spun down, and washed several times. The final pellets
were dissolved in 1% SDS and separated on an SDS–15 to 20% exponential
gradient polyacrylamide gel.
DNA analysis. Total DNA was isolated from cells by direct lysis in PCR buffer
(10 mM Tris-HCl [pH 8.4], 50 mM KCl, 1 mM MgCl2) containing 100 mg of
proteinase K per ml and 0.5% Tween 20 (22). Quantification of mtDNA in total
cell DNA samples was carried out by slot blot hybridization, by using the clone
pTZ18-K4 (containing the EcoRI-KpnI fragment of human mtDNA between
positions 41 and 2578), labeled by random priming, as a probe. To correct for
possible quantitative variations among different DNA samples, the same mem-
brane was probed with a nuclear 28S rRNA gene fragment, constructed by PCR
amplification using oligonucleotides corresponding to positions 1503 to 1522 and
1981 to 2000 in the 28S rRNA gene (12), purified on an agarose gel, and 32P
labeled by random priming. For DNA sequencing, the segments of the VA2B,
C4T, and C5T mtDNAs between positions 10420 and 12200, which contain the
ND4L and the ND4 genes, were amplified by PCR with appropriate oligonucle-
otides in two overlapping portions 989 and 896 bp in length. Similarly, the
segments of VA2B, C8T, and C9T mtDNAs between positions 12282 and 14177,
which contain the ND5 gene, and the segments of VA2B and C6T mtDNAs
between positions 3274 and 4329, which contain the ND1 gene, were amplified
(the ND5-containing segment in two overlapping portions of 978 and 1111 bp).
The PCR products were electrophoresed on an agarose gel in Tris-acetate-
EDTA, eluted from the gel, and ethanol precipitated, and the purified double-
stranded fragments were directly sequenced by the chain termination method
(29) using CircumVent DNA polymerase (New England Biolabs) and 35S-dATP.
The products of the sequencing reactions were separated on a 0.4-mm-thick 6%
polyacrylamide–7 M urea gel.
Quantification of the mtDNA frameshift mutations was carried out by allele-
specific termination of primer extension, which is illustrated schematically in Fig.
1a and b for the ND4 and ND5 gene mutations, respectively. A 346-bp segment
between positions 10762 and 11108, containing the ND4 mutation (a C insertion
in a row of six C residues at positions 10947 to 10952), and a 359-bp segment of
mtDNA between positions 12282 and 12641, containing the ND5 mutation (an A
insertion in a row of eight A residues at positions 12417 to 12424), were amplified
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with Taq polymerase, using 106 to 107 template molecules. The two amplified
fragments were separated from free nucleotides on a 1% Tris-acetate-EDTA–
agarose gel, eluted from the gel overnight, and ethanol precipitated. Solutions in
Sequenase buffer that contained the amplified DNA fragment and a correspond-
ing 59-32P-labeled primer (of 24 bp [positions 10976 to 10953) for the ND4 gene
mutation and 20 bp [positions 12398 to 12427] for the ND5 gene mutation) in a
1:1 molar ratio were prepared. Nucleotide concentrations were 60 mMdGTP and
500 mM ddTTP for the quantification of the C insertion in the ND4 gene and 60
mM dATP and 250 mM ddCTP for the quantification of the A insertion in the
ND5 gene. The mixtures were heated to 958C for 3 min and chilled on ice. After
addition of 1 ml of diluted Sequenase, they were incubated for 5 min at 458C. The
products (31 and 32 bp for the ND4 mutation and 29 and 30 bp for the ND5
mutation) were denatured and separated on a 50-cm-long 20% polyacrylamide–6
M urea gel. The correct sizes of the products were checked separately by elec-
trophoresis in a sequencing gel. Quantification of the intensity of the bands was
done by using a phosphorimager and the IMAGE-QUANT program.
Quantification of a G3A transition in the ND1 gene at position 3496, which
causes the disappearance of an AciI site, was carried out by amplifying a 354-bp
segment of mtDNA between positions 3274 and 3628, which encompasses the
mutation, digesting it with AciI, and analyzing it by electrophoresis through an
8% polyacrylamide gel and scanning the ethidium-bromide stained gel with an
LKB laser densitometer. The amplified fragment of wild-type mtDNA contains
two AciI cutting sites separated from each other by 30 nucleotides. Cutting at the
39-end-proximal site cleaves off a 104-bp fragment, which serves as an internal
control for completion of digestion. The remaining 251-bp fragment has an
additional AciI site that disappears as a result of the G3A transition. In wild-
type mtDNA, this fragment is shortened by 30 nucleotides because of cleavage at
the second AciI site. The ratio between the 221- and the 251-bp fragments was
used for the quantification of the mutation.
RESULTS
Six of eight rotenone-resistant mutants show a decreased
complex I activity due to an mtDNA mutation. The original
goal of these experiments was to isolate mutants of the human
cell line VA2B (27) which were resistant to rotenone, a specific
inhibitor of complex I. Since the ND1 gene encodes the sub-
unit which binds rotenone (6), it was hoped that, at least in
some of the isolated mutants, the resistance may have been
due to a mutation in this mtDNA gene. Preliminary experi-
ments showed that both the growth capacity in mass culture
and the plating efficiency of VA2B cells were significantly af-
fected by rotenone concentrations as low as 0.2 mM, with
complete inhibition by 1 mM drug (Fig. 2a). An intriguing
observation was that the growth of mtDNA-less r0206 cells was
also severely inhibited by 0.25 mM rotenone and totally inhib-
ited by 0.5 to 1.0 mM concentrations of the drug (Fig. 2b).
After ;4 3 106 VA2B cells were exposed to 0.4 mM rote-
none for 3 weeks, ;1,400 clones were obtained. Ten randomly
chosen independent clones were subjected to stepwise-in-
creased concentrations of rotenone, starting from 0.4 mM, and
eight clones (designated C2 and C4 to C10) were adapted to
grow in the presence of a 1 mM concentration of the drug, with
doubling times of between 26 and 171 h (Fig. 2a). Interestingly,
the growth rates of several transformants tested (C4, C5, and
C6) were found to be increased substantially (by a factor of
about 2) by addition of 50 mg of uridine per ml to the medium.
This observation pointed to the occurrence in these transfor-
mants of a respiration defect, induced by a mutation or by
rotenone action, which affected the pyrimidine synthesis ca-
pacity of the cell; in fact, it is known that the activity of dihy-
droorotate dehydrogenase, a key enzyme in this biosynthetic
pathway, depends on a functional respiratory chain (14).
Support for the suggestion of the presence of a respiratory
defect in at least some of the original VA2B mutants was
provided by a direct investigation of their respiratory capacity.
In fact, a preliminary analysis of some of these mutants (C4,
C6, C8, and C10) revealed decreased O2 consumption (0.5 to
1.2 fmol/min per cell, compared with values of 3.0 to 3.5 fmol/
min per cell obtained for VA2B cells). The residual respiratory
capacity of the mutants appeared to be sensitive to 0.1 mM
rotenone, as was the respiratory capacity of VA2B cells (data
not shown). By using digitonin-permeabilized cells (13), it was
possible to measure the activity of the individual components
of the mitochondrial respiratory chain in the rotenone-resis-
tant mutants. Of the eight mutants, six (C2, C4, C5, C6, C8,
and C9) showed, surprisingly, a specific reduction of complex I
activity, with complexes III and IV being apparently function-
ally normal (Fig. 3a). Clone C10 showed a decreased activity of
all three enzyme complexes of the respiratory chain and was
FIG. 1. Illustration of the approach used for the quantification of the insertion of a C residue in the ND4 gene (a) and of an A residue in the ND5 gene (b). A
dideoxynucleoside triphosphate (asterisk) is indicated. H, heavy strand; L, light strand.
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excluded from further analysis; clone C7 showed a normal
activity of the three enzymes and was utilized as a control.
In order to investigate the genetic origins of the rotenone
resistance and of the respiratory defect of the isolated VA2B
variants and the relationship between the two phenomena,
advantage was taken of the possibility of repopulating
mtDNA-less (r0) 143B.206 cells with exogenous mitochon-
dria (23). This approach, in fact, is a very convenient means
of testing whether the rotenone resistance and the respira-
tory defect of the isolated variants were due to a mutation(s)
in a nuclear or a mitochondrial gene(s). By using enucleated
cells (cytoplasts), the mitochondria from seven of the mu-
tants (C2 and C4 to C9) were transferred into r0 cells, thus
producing transmitochondrial cell lines containing the
mtDNA of the original isolates in the constant nuclear back-
ground of the r0 cells (23). Surprisingly, it was found that all
transformants showed an even greater sensitivity to rote-
none in their growth capacity than 143B.TK2 and r0 cells
(Fig. 2b). Thus, it was concluded that the drug resistance of
the original mutants was due to a nuclear mutation(s).
In contrast to the rotenone resistance, both the decrease in
overall respiratory capacity and the specific complex I defect of
the six respiration-deficient mutants (C2, C4, C5, C6, C8, and
C9) were transferred into r0 cells together with their mtDNA
(Fig. 3b). These results were consistent with the idea that a
mitochondrial mutation was the cause of the reduction in res-
piration and complex I activity. This putative mutation did not
produce rotenone resistance of complex I, since the residual
respiration and complex I activity of the transformants were
found to be rotenone sensitive, like those of the original mu-
tants tested. An analysis of the mtDNA contents of the trans-
formants showed that they did not differ significantly (between
212 and 128%) from the 143B.TK2 value, except for the
content of C4T, which was;50% of the 143B.TK2 value (data
not shown). It seemed unlikely that a defect in the transport of
the substrates or in the activity of the corresponding dehydro-
genases was responsible for the low complex I activity, since
FIG. 2. Growth of VA2B cells and the indicated rotenone-resistant mutants
(a) and of r0 and 143B.TK2 cells and the indicated transformants (b) in the
presence of different concentrations of rotenone. The total numbers of cells in
plates seeded with 33 105 (a) or 23 105 (b) cells after 5 days of growth in media
containing 0 (n), 0.25 (o), 0.50 (1), or 1.0 (h) mM rotenone are shown.
FIG. 3. Activities of the enzymes of the mitochondrial respiratory chain in
the mutant clones (a) and the corresponding r0 cell transformants (b). By using
;5 3 106 digitonin-permeabilized cells, the activities of the various components
of the respiratory chain were determined as respiration dependent on malate-
glutamate (n), glycero-3-phosphate–succinate (o), and ascorbate-TMPD (h).
Error bars represent 2 standard errors.
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the enzymes involved in substrate transport and the dehydro-
genases are nucleus encoded. To verify the above conclusion,
the activity of complex I in partially purified mitochondrial
membranes was measured, using NADH and a water-soluble
ubiquinone analog (Q1) to circumvent any transport problem
(Table 1). The NADH:K3Fe(CN)6 oxidoreductase activity of
the membranes was also measured. The latter reaction is cat-
alyzed by the nucleus-encoded flavoprotein fragment of the
enzyme (11). If in mammalian cells the matrix arm of complex
I, which includes the flavoprotein fragment, is assembled in-
dependently from the membrane arm, as has been shown to be
the case for N. crassa (35), it seemed likely that the NADH:
K3Fe(CN)6 oxidoreductase activity would not be affected by an
mtDNA mutation. This lack of effect of the mutation on the
NADH:K3Fe(CN)6 oxidoreductase activity had indeed been
shown previously for the C4T mutation (16) and appeared to
be true also for the mtDNA mutations of the other rotenone-
resistant clones (Table 1). Thus, this activity could be used to
correct for differences in mitochondrial content among the
crude mitochondrial membrane preparations isolated from dif-
ferent clones. The corrected activities are shown in Table 1.
The results of the spectrophotometric analysis confirm the
decreases in complex I activity detected by the polarographic
measurements for the transformants.
Protein synthesis defects in complex I-deficient transfor-
mants. In order to obtain some indications as to the possible
sites of the mutations responsible for the complex I defect in
the six mutant cell lines and in the derived transformant cell
lines described above, the mitochondrial translation products
of the transformants were labeled for 2 h with [35S]methionine
in the presence of emetine (to block cytoplasmic protein syn-
thesis). As can be seen in Fig. 4, there was no significant
difference in the overall labeling of the mitochondrial transla-
tion products between any of the transformants and VA2B
cells. However, several transformants exhibited some differ-
ences in the relative labeling of the various mtDNA-encoded
polypeptides in comparison with the pattern of the VA2B cell
line. One striking difference was the previously reported com-
plete disappearance of the ND4 gene product in the pattern
from the C4T transformant (16), while the labeling of the other
mtDNA-encoded complex I subunits of this transformant ap-
peared to be normal. Similarly, there was a specific decrease in
the labeling of the ND4 subunit in the C5T transformant.
Figure 4 also shows that the translation product corresponding
to the ND5 subunit was not detectable in the C9T transfor-
mant and was strongly decreased in the C8T transformant. By
contrast, transformants C2T and C6T showed no difference
from VA2B cells in the relative labeling or electrophoretic
migration of their mitochondrial translation products. Experi-
ments in which the transformants were subjected to short (20-
or 40-min) [35S]methionine pulses showed that the rate of
labeling of their mitochondrial translation products did not
differ significantly from that observed in VA2B cells, except for
a 50 to 60% decrease in the case of the C2T and C9T trans-
formants.
Four complex I-deficient mutants exhibit frameshift muta-
tions in their mtDNA. In previous work (16), by PCR ampli-
fication and subsequent sequencing of the mtDNA segment
encompassing the ND4 gene, the mutation in the C4T trans-
formant had been identified as an insertion of a cytidine resi-
due in a stretch of six C’s at positions 10947 to 10952 (Fig. 5a).
As described in the previous paper (16), the insertion causes a
frameshift and the creation of a stop codon ;150 bp down-
stream; this results in the formation of a premature termina-
tion product of ;13 kDa, which appears to be rapidly de-
graded. In the present work, PCR amplification and DNA
sequencing analysis showed that the C5T transformant carried
the same mutation present in C4T but in a heteroplasmic form
(Fig. 5a). This heteroplasmicity produced the appearance of
double bands in the region of the sequencing gel downstream
of the insertion point (Fig. 5a).
In order to quantify the mutation in the C4T and C5T cell
lines, an assay based on allele-specific termination of primer
extension was developed (Fig. 1a). A 24-bp-long primer ending
TABLE 1. Measurement of NADH:Q1 and NADH:Fe(CN)6
oxidoreductase activities in mitochondrial membranes isolated from
various transformants and VA2B cells
Cell line






VA2B 7.6 (0) 210 (15) 3.6 (0.3)
C2T 2.1 (0.3) 263 (13) 0.80 (0.12)
C4T 0 281 (35) 0
C5T 0.2 (0) 343 (61) 0.06 (0.01)
C6T 3.9 (0.1) 485 (21) 0.80 (0.04)
C7T 4.9 (0.3) 253 (58) 1.9 (0.5)
C8T 1.5 (0.3) 240 (10) 0.63 (0.13)
C9T 0.3 (0.1) 264 (5) 0.11 (0.04)
a Determinations were made in duplicate.
FIG. 4. Electrophoretic patterns of newly synthesized mitochondrial transla-
tion products in VA2B cells and different transformants. Shown are the fluoro-
grams, after polyacrylamide gradient gel electrophoresis, of samples of total cell
lysates from VA2B (48 mg of protein), C2T (94 mg), C4T (26 mg), C5T (100 mg),
C6T (81 mg), C7T (78 mg), C8T (44 mg), and C9T (150 mg) cells exposed to
[35S]methionine for 2 h in the presence of 100 mg of emetine per ml. The
individual mitochondrial translation products were identified according to ref-
erence 4. COI, COII, and COIII, subunits I, II, and III of cytochrome c oxidase,
respectively; ND1, ND2, ND3, ND4, ND4L, ND5, and ND6, subunits 1, 2, 3, 4,
4L, 5, and 6 of respiratory chain NADH dehydrogenase, respectively; A6 and A8,
subunits 6 and 8 of the H1-ATPase, respectively; CYTb, apocytochrome b.
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just at the nucleotide preceding the six C’s was synthesized and
32P labeled at the 59 end. A portion of the ND4 gene (350 bp)
encompassing the mutation was amplified by PCR of total
DNA samples from VA2B and various transformants and pu-
rified over a 1% agarose gel. The primer was annealed to the
PCR product, and the mixture was then incubated with Seque-
nase. Only dGTP and ddTTP were present in the mixture, so
that the enzyme could attach six or seven G residues to the
primer and then incorporate ddTTP, which terminated the
elongation. This resulted in products that were 31 or 32 bp
long, depending on the number of C residues in the template,
and that could be separated on a 20% polyacrylamide–6 M
urea sequencing gel (Fig. 6a). A control assay using a cloned
fragment of mtDNA containing the C stretch showed that the
PCR amplification step did not produce detectable amounts of
the C insertion. Besides a few artifacts of unknown origin, the
control assay with the cloned fragment yielded a clear band
corresponding to six C’s (Fig. 6a). The correct size of the
product was checked by electrophoresis on a sequencing gel
(data not shown). VA2B cells showed no detectable mutant
mtDNA, whereas the C4T transformant exhibited no trace of
wild-type DNA; by contrast, transformant C5T contained
about 34% wild-type DNA. Transformant C6T showed a weak
signal corresponding to the wild-type 6-C band, but even after
longer exposures of the autoradiogram, no signal correspond-
ing to the 7-C band could be detected.
PCR amplification and subsequent sequencing of an mtDNA
segment encompassing the ND5 gene led to the discovery that the
mtDNA of C9T carries an insertion in the 59-end-proximal por-
tion of the ND5 gene. A stretch of eight A’s, starting at posi-
tion 12417 of the mtDNA, was found to be elongated by an
additional A in the transformant (Fig. 5b). Again, this insertion
causes a frameshift and leads to the formation of a premature
termination product of ;6.9 kDa. No band corresponding to
such a product was visible in the protein labeling pattern of the
C9T transformant (Fig. 4), probably because of its rapid deg-
radation, as observed in a previous study (16) for the prema-
ture termination product of transformant C4T. A primer ex-
tension assay similar to that described above was used to
quantify the mutation, this time using dATP and ddCTP (Fig.
1b). The experiment (Fig. 6b) again showed no detectable
mutant mtDNA in VA2B cells. By contrast, C9T exhibited a
very small amount of wild-type mtDNA (;4%); this amount of
wild-type mtDNA could account for the residual complex I
activity of the transformant, which was estimated to be ;12%
of the wild-type activity by polarography and ;3% by enzy-
matic assays. However, the expression of the very small amount
of wild-type mtDNA did not lead to a detectable level of ND5
labeling in the 2-h [35S]methionine pulse-labeling experiment
(Fig. 4). The same A insertion in the ND5 gene present in C9T
was found in the C8T transformant but in heteroplasmic form
(Fig. 5b). This heteroplasmicity was responsible for the appear-
ance of double bands in the region of the sequencing gel
downstream of the insertion point. By the primer extension
assay, it was determined that C8T contains about 28% wild-
type mtDNA (Fig. 6b).
The mtDNA mutations associated with the two remaining
complex I-deficient mutants (C2 and C6) have not yet been
identified. Sequencing of the ND1 gene of the C6T transfor-
mant revealed the presence of three differences from the Cam-
bridge sequence. Two of these differences were synonymous,
apparently homoplasmic base substitutions present also in
VA2B and presumably represented mtDNA polymorphisms.
The third difference, a G-to-A transition at position 3496
which produced the change of a fairly conserved Ala to an Asn
in the protein, was present in heteroplasmic form in the pa-
rental mtDNA. The changed amino acid is at the beginning of
the second conserved predicted membrane-spanning helix (8),
and the additional charge may in principle hinder the appro-
priate folding of the ND1 subunit. As shown in Fig. 7, this
mutation, which causes the disappearance of an AciI site and
can therefore be easily detected, was found to occur in hetero-
plasmic form with predominance of the wild-type gene in
VA2B and C8T and with predominance of the mutant gene in
C9T and in homoplasmic form in C2T, C4T, C5T, C6T, and
C7T. The mutation does not appear to affect complex I activity,
as shown most clearly by its presence in homoplasmic form in
C7T, which has a normal complex I activity (Fig. 3b).
Analysis of the assembly of complex I in the transformants.
In order to address the question of whether the assembly of
complex I is affected in the various transformants analyzed in
this study, antibodies against the nucleus-encoded 49-kDa
iron-sulfur subunit of the bovine enzyme, which is part of the
matrix arm, were used to immunoprecipitate whole complex I
(2). In these experiments, only the mtDNA-encoded subunits
that were assembled into complex I were expected to be
coprecipitated. The mtDNA translation products of several
transformants, pregrown for 22 h in the presence of chloram-
phenicol (to accumulate nucleus-encoded subunits of complex
I), were labeled for 2 h with [35S]methionine in the presence of
cycloheximide (to inhibit cytosolic protein synthesis) and then
chased for 15 h in the absence of inhibitors. The mitochondrial
fraction was then isolated from each transformant. One por-
tion of it was utilized to make an SDS lysate for analysis of the
FIG. 5. (a) Portion of the sequence of the ND4 gene from VA2B, C4T, and
C5T cells (between positions 10941 and 10970), showing the insertion of a C
residue in the C4T and C5T sequences. The single-stranded PCR product cor-
responding to the coding (light) strand was used as a template for sequencing by
the chain termination method, and the sequence obtained was converted to the
light-strand sequence for convenience. (b) Portion of the sequence of the ND5
gene from C9T, VA2B, and C8T cells (between positions 12411 and 12434),
showing the insertion of an A residue in the C9T and C8T sequences.
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mitochondrial translation products. Another portion was lysed
with Triton X-100, and equal samples of it were incubated with
gamma globulins from an antiserum against the purified bo-
vine 49-kDa subunit to precipitate the assembled complex I,
from an antiserum against human COII to precipitate the
assembled cytochrome c oxidase complex (26), or from normal
rabbit serum. Proteins of the SDS mitochondrial lysate and of
the Zysorbin-adsorbed and washed immunoprecipitates were
separated by SDS-polyacrylamide gel electrophoresis, and the
gels were subjected to fluorography.
As shown in Fig. 8a, the electrophoretic pattern of the SDS
mitochondrial lysate from pulse-chased VA2B cells revealed all
the mitochondrial translation products, with a few extra bands
in the high-molecular-weight region, representing cytoplasmic
proteins labeled during the chase (2). The presence of closely
migrating contaminating bands made the recognition of the
ND5 subunit in the VA2B pattern, as well as in the patterns for
the transformants, difficult. In the pattern for C4T cells, as
previously reported (16), the labeled mtDNA-encoded sub-
units of complex III, complex IV, and H1-ATPase were
present in the same amount as in the VA2B pattern; by con-
trast, several of the mtDNA-encoded subunits of NADH de-
hydrogenase were apparently absent (ND4) or strongly re-
duced (ND2, ND6, and ND3), a result which pointed to their
instability, presumably resulting from defective assembly. Only
the ND1 and ND4L subunits were present in C4T in normal
amounts (Fig. 8a). In the pattern from C9T, the ND5 subunit
was apparently absent, as expected, while the ND4, ND2, ND1,
ND3, and ND4L subunits were present in comparable or only
slightly decreased amounts relative to those in the VA2B pat-
tern. Only the ND6 subunit appeared to be significantly de-
creased (Fig. 8a). In the C6T pattern, there was a general
decrease in the labeling of the mitochondrial translation prod-
ucts to about one-third of the levels observed in VA2B cells
and the other transformants, but the relative labeling of the
various mtDNA-encoded subunits of NADH dehydrogenase
seemed to be comparable to that observed in the VA2B pattern
(Fig. 8a). A repeat of the pulse-chase experiment confirmed
the reduction in the labeling of the mitochondrially synthesized
polypeptides in this transformant. Since, as mentioned above,
the labeling of the mitochondrial translation products in C6T
FIG. 6. Results of the quantification of the insertions in the ND4 (a) and ND5 (b) genes in VA2B cells, in various transformants, and in cloned template DNA (lanes
Cntr), carried out by using allele-specific termination of primer extension. The products of analysis were separated on a 20% polyacrylamide–7 M urea sequencing gel.
MT, mutant product; WT, wild-type product; PR, unextended primer.
FIG. 7. Detection of ND1 gene mutation at position 3496 in total DNA
samples from VA2B cells and various transformants. The sizes of the uncut (UC)
PCR product (354 bp) and of the three fragments produced by AciI digestion of
the VA2B PCR product (251, 221, and 104 bp) are indicated. M, molecular
weight marker (MspI-digested pBluescript KS1 DNA; fragment sizes: 710, 489,
404, 367, 242, 190, 147, 118, 110, 67, and 57 bp).
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after a short pulse or a 2-h [35S]methionine pulse was not
significantly different from that observed in VA2B cells, it
seems likely that the decreased protein labeling in the pulse-
chased cells reflected a lesser stability of the mitochondrial
translation products, possibly due to the particular nuclear
background of this transformant. To correct for this difference
in labeling, an approximately threefold-greater amount of the
C6T lysate, compared with the other lysates, was used in the
immunoprecipitation experiments.
A control experiment in which the whole cytochrome c ox-
idase was precipitated from Triton X-100 mitochondrial lysates
with antibodies against the C-terminal undecapeptide of sub-
unit II of the human enzyme (26) showed no significant dif-
ference in extent of enzyme complex immunoprecipitation be-
tween the lysate from VA2B cells and the lysates from the
transformants, as judged from the intensities of the COI, COII,
and COIII bands (Fig. 8a). The anti-49-kDa-subunit antibodies
coprecipitated from the VA2B Triton X-100 mitochondrial
lysate all mtDNA-encoded subunits of complex I (Fig. 8b); the
electrophoretic pattern of the immunoprecipitate exhibited a
small amount of spurious bands, most of which were, however,
present also in the precipitate obtained with the normal-se-
rum-treated lysate. The immunoprecipitates from the C2T and
C6T transformants exhibited all the mtDNA-encoded subunits
of complex I, although in reduced amounts compared with
those of the VA2B pattern (Fig. 8b). In contrast, as reported
earlier (16), the immunoprecipitate obtained with the C4T
Triton X-100 mitochondrial lysate completely lacked the ND4
subunit and contained only trace amounts of the other
mtDNA-encoded subunits (Fig. 8b).
The immunoprecipitate from the C9T transformant exhib-
ited a different pattern, characterized by the apparent absence
of the ND5 subunit above the background level present in the
normal-serum control (Fig. 8b). The remaining mtDNA-en-
coded complex I subunits were present in the immunoprecipi-
tate (the ND1 and ND2 subunits being relatively abundant),
but they appeared to be significantly reduced in amount in
comparison with those in the VA2B pattern. The above obser-
vations strongly suggest that the lack of the ND5 subunit does
not prevent the assembly of the membrane arm of complex I
but reduces the efficiency of this process or affects the stability
of the complex in Triton X-100.
DISCUSSION
The main conclusion of this study is that selection for resis-
tance to high concentrations of rotenone, a specific inhibitor of
respiratory NADH dehydrogenase, can be an efficient means
for isolating from the human cell line VA2B mutants affected
in any of the mtDNA-encoded subunits of the first respiratory
enzyme. Originally devised as an approach for the isolation of
mutants affected in the ND1 gene, which encodes the complex
I subunit that binds rotenone (6), the selection scheme used
here yielded, surprisingly, a variety of mutants altered in dif-
ferent subunits of the enzyme. Considering the fact that six of
eight mutants showed an mtDNA-encoded complex I defect, it
is clear that this system will prove invaluable for the genetic
dissection of complex I and for understanding the still-elusive
functional role of the mtDNA-encoded subunits of this impor-
tant enzyme. This is particularly significant in view of the in-
FIG. 8. (a) Electrophoretic patterns of samples of SDS mitochondrial lysates of [35S]methionine-pulse-chased VA2B, C2T, C4T, C6T, and C9T cells (lanes CH) and
of immunoprecipitates obtained by incubating samples of 0.5% Triton X-100 mitochondrial lysates of the pulse-chased cells with gamma globulins from an antiserum
against the human COII subunit (lanes COII). (b) Electrophoretic patterns of immunoprecipitates obtained by incubating samples of 0.5% Triton X-100 mitochondrial
lysates of [35S]methionine-pulse-chased VA2B, C2T, C4T, C6T, and C9T cells with gamma globulins from an antiserum against the bovine 49-kDa subunit (lanes 49)
(2) or from normal rabbit serum (lanes NS). See Materials and Methods for details.
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creasingly clear involvement of complex I in human diseases
(32). Furthermore, the present technology for transferring
mtDNA mutations into r0 cells and the availability of null
mutants lacking one of the mtDNA-encoded subunits of com-
plex I open exciting possibilities for investigation.
Possible mechanism of selection. The lack of transfer into r0
cells of the rotenone resistance together with the mitochondria
from the drug-resistant mutants implied that a nuclear muta-
tion was responsible for the cell resistance to high concentra-
tions of rotenone. The VA2B cells used for selection had not
been mutagenized, and one must therefore assume that the
initial nuclear mutation producing resistance to 0.4 mM rote-
none preexisted in the VA2B cell population. The observation
that even r0 cells, which lack a respiratory chain, were sensitive
to the high concentrations (0.4 to 1 mM) of rotenone used for
the isolation of drug-resistant mutants indicated that the drug
affected another vital cell activity besides respiratory function.
As to the nature of the nuclear mutation that conferred resis-
tance to high concentrations of rotenone upon the original
VA2B mutants investigated in this study, considering the
chemical structure of this drug, it seems possible that it in-
volved an overexpression and/or amplification of the genes
encoding the P-glycoproteins, the cell membrane-associated,
energy-dependent drug efflux pumps which are responsible for
the multi-drug resistance phenotype (7).
In light of the observations discussed above, the respiration
defects transmissible with mitochondria into r0 cells which
were detected in nearly all the rotenone-resistant mutants in-
vestigated in this study must have resulted from a selection of
mtDNA mutations conferring respiration deficiency during the
prolonged exposure of the cells to high concentrations of ro-
tenone. It seems reasonable to assume that, in the presence of
the increasingly high rotenone concentrations used for selec-
tion, relatively small amounts of the drug may have accumu-
lated in the cells, approaching or surpassing the 0.1 or 0.2 mM
level, which was shown to be sufficient to inhibit complex I
activity and partially affect cell growth. Under these conditions,
any mtDNA mutation which had made a cell respiration defi-
cient, with an accompanying adaptation to exclusive or pre-
dominant glycolytic ATP production (5), would have also
made that cell relatively respiration independent and provided
it with a growth advantage, even if slight. The single clone,
among the eight isolated, that exhibited normal respiration and
normal complex I activity may have represented a case in which
a nuclear mutation producing a higher level of resistance to
rotenone prevented the accumulation in the cell of damaging
concentrations of the drug. A possible mechanism for the es-
tablishment of an mtDNA mutation in the rotenone-resistant
clones might have involved a replicative advantage of the mu-
tated mtDNA molecules, such as that recently described for
mtDNA carrying the mutation associated with MELAS syn-
drome (mitochondrial encephalomyopathy, lactic acidosis, and
stroke-like episode syndrome) (39). In the absence of rotenone
selection, such hyperreplication of the mutated mtDNA would
not be favored, because intercellular selection would tend to
eliminate the cells more severely compromised in their respi-
ratory activity by the mutation. By contrast, in the presence of
rotenone, which strongly reduces the respiratory activity in all
cells, the cells with amplified mutant molecules would not be
selected against but would, on the contrary, be selected for
because of the progressive adaptation to glycolytic metabolism
accompanying the mutation amplification.
In regard to the origin of the mtDNA mutations, it is likely
that, like the mutation conferring rotenone resistance, they
existed in the VA2B cell population prior to the rotenone
selection. The evidence concerning the occurrence of two dis-
tinct mtDNA frameshift mutations, each found in two inde-
pendent clones, supports this conclusion, and this probably
also applies to the mtDNA mutations of C2T and C6T which
have not yet been identified. The ND13496 mutation detected
in the present work provides a clear example of a mutation
preexisting in heteroplasmic form in VA2B cells which subse-
quently shifted towards homoplasmy to a variable extent in
different rotenone-resistant clones. However, in this case, the
shift may have been caused by random segregation, since there
was no evidence of a deleterious effect of this mutation on the
cell respiration capacity. It should be mentioned that in a
recently completed study, in which single mitochondria from
HeLa cells were microinjected into r0206 cells, about 30% of
the transformants were shown to be respiration deficient be-
cause of mtDNA mutations in complex I subunits (1a). This
work strongly suggests that untreated HeLa cells carry mtDNA
mutations in genes encoding subunits of complex I. It is a
reasonable hypothesis that mutations of mtDNA arise contin-
uously during the growth of established cell lines and that the
mutations may be either diluted out or selected for if appro-
priate growth conditions are applied. Furthermore, it can be
expected that treatment of the cells with mutagens prior to
rotenone treatment would increase the frequency of isolation
of desired mtDNA mutations affecting subunits of complex I.
Obviously, more work is needed to understand the selection
mechanism at work in the VA2B system studied here, as well as
to determine whether the same mechanism operates in other
established cell lines.
Six of eight rotenone-resistant mutants exhibit a specific
mtDNA-linked complex I defect. Polarographic analysis of the
seven rotenone-resistant, respiration-deficient mutants iso-
lated here revealed, surprisingly, that six of them exhibited a
specific complex I defect. Furthermore, the transfer of this
defect with mitochondria into r0 cells clearly indicated that an
mtDNA mutation underlay the enzyme deficiency. According
to the selection mechanism proposed above, any mtDNA mu-
tation affecting a subunit of complex III or IV so as to com-
promise respiration should have also been selected for. A pos-
sible explanation for the preferential targeting by mutations of
the genes for complex I subunits in the mutants analyzed here
is that deleterious mutations in any subunit of complex III or
IV or in any mtDNA-encoded component of the mitochondrial
translation apparatus would have compromised the cell capac-
ity for pyrimidine biosynthesis because of the dependence of
dihydroorotate dehydrogenase activity on a functional respira-
tory chain downstream of NADH dehydrogenase (14). It thus
appears that, under the conditions used in the present work,
complex I activity is not indispensable for the growth of the
cells.
The measurements of NADH:Q1 oxidoreductase activity in
the partially purified mitochondrial membranes from the r0
cell transformants derived from the rotenone-resistant mutants
investigated in this study gave results which were reasonably
consistent with the polarographic data. As previously observed
for the transformant derived from the C4 mutant, lacking the
ND4 subunit (16), the NADH:K3Fe(CN)6 oxidoreductase ac-
tivity was unaffected in the transformants derived from the five
other complex I-deficient mutants, pointing to the normal
assembly and association with the membrane of the nucleus-
encoded flavoprotein fragment (11). The mitochondrial
membranes from transformant C6T exhibited an unusually
high NADH:K3Fe(CN)6 oxidoreductase activity and a
higher NADH:Q1 oxidoreductase activity than expected
from the polarography data; it is possible that this result
reflects a higher mitochondrial content in the C6T mem-
brane preparation.
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Frameshifts in mtDNA of complex I-deficient mutants. A
remarkable observation made in the present work is that four
of the six complex I-deficient mtDNA mutants investigated
exhibited frameshifts in the DNA that created stop codons
downstream and caused the formation of unstable, prema-
turely terminated translation products. As discussed above,
there is reason to believe that the frameshift mutations preex-
isted in the VA2B cell population, although in very small
amounts not detectable in our assays. In human mtDNA, there
are 35 homopolymeric sequences of six or more identical res-
idues (1). These homopolymeric stretches could be hot spots
for frameshifts because of stuttering by the DNA polymerase.
It seems very likely that, during the long rotenone selection,
there was a shift towards homoplasmy of the ND4 and ND5
frameshift mutations detected in the present work, either be-
cause of a growth advantage of cells with higher levels of
frameshifts or because of a replicative advantage of frame-
shifted molecules, as discussed above. This process resulted in
a homoplasmic or near-homoplasmic genotype in C4T and
C9T and a heteroplasmic genotype in C5T and C8T.
Frameshift mutations in a run of five T residues leading to
premature termination of translation have been previously de-
scribed for the Saccharomyces cerevisiae mitochondrial gene
encoding subunit COII of cytochrome c oxidase (9). By con-
trast, it is intriguing that among the mtDNA mutations in
protein-coding genes associated with diseases in humans, no
frameshift has been described so far (32).
Functional effects of the ND4 and ND5 frameshift muta-
tions. There is considerable evidence to support the conclusion
that the ND4 and ND5 gene frameshifts were responsible for
the complex I defect detected in the C4T and C9T transfor-
mants, respectively. Although one cannot absolutely exclude
the presence of deleterious mutations in mtDNA genes encod-
ing other subunits of NADH dehydrogenase in these transfor-
mants, the presence of these subunits in normal relative
amounts and with the expected electrophoretic mobilities in
the protein labeling patterns, after short and long pulses, of
C4T and C9T makes the lack of the ND4 and ND5 gene
products, respectively, the most plausible cause of the complex
I defect. Also, the occurrence of the ND4 and ND5 gene
frameshifts in heteroplasmic form in C5T and C8T, respec-
tively, which exhibited residual complex I activities of 25 and
46% and a reasonably proportional wild-type gene content (34
and 28%, respectively), is consistent with the exclusive patho-
genetic role of these frameshifts. It should be noted that nei-
ther frameshift mutation was detectable in VA2B cells or in the
five other transformant clones analyzed. These observations, as
well as the apparent absence so far of deleterious mutations
affecting complexes III and IV, indicate that the occurrence of
mtDNA mutations causing a defective phenotype was rela-
tively rare in the transformants analyzed here. This is consis-
tent with the low overall frequency of mtDNA mutations pro-
ducing respiration defects which were detected in the present
work, as well as in a previous screening of VA2B cells for the
respiration-deficient phenotype (36). Therefore, it seems jus-
tified to conclude that the probability that any one of the
mutants analyzed here, in particular, any one of the frame-
shift mutants, carries a second deleterious mutation is very
low.
The total lack of complex I activity and the failure of the
mtDNA-encoded subunits of this enzyme to assemble in the
C4T transformant, which completely lacks the ND4 subunit,
had been previously described (16). A new, significant result
reported here is the substantial lack of complex I activity in the
transformant C9T, which exhibited a near-complete absence of
the ND5 subunit. This is the first evidence reported that indi-
cates that the ND5 subunit is essential for complex I activity in
mammalian cells. In contrast to the situation observed with the
C4T transformant, antibodies against the 49-kDa subunit pre-
cipitated from a C9T mitochondrial lysate all mtDNA-encoded
subunits, except ND5, although in reduced amounts, compared
with those from VA2B, C2T, and C6T. Thus, the absence of the
ND5 subunit did not prevent the assembly of the remaining
mtDNA-encoded subunits. The reduced level of immunopre-
cipitation of these subunits from the C9T lysate may indicate a
lower efficiency of assembly or an instability of the membrane
arm of the enzyme in the absence of the ND5 subunit in the
C9T transformant.
The immunoprecipitate obtained from the C2T and C6T
mitochondrial lysates exhibited all the mtDNA-encoded
subunits, including ND4 and ND5, indicating that the mu-
tation causing the complex I defect did not affect the assem-
bly of the membrane arm of the enzyme in these transfor-
mants.
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